WEBULL
WebtradeDownload

STERIS (STE) Stock May Be 8% Overvalued On Current Cash Flow

Simply Wall St · 4d ago

STERIS has delivered a 12.5% share price gain over the past three years, which puts a spotlight on whether the current US$232.14 level is properly backed by the cash the business can generate. With the focus squarely on its cash flows, the question now is how that recent performance lines up against an intrinsic value estimate built from those streams.

  • The 12.5% return over three years puts real money on the line for anyone asking whether that performance is supported by the cash the company can reasonably produce.
  • The group’s role in sterilization and infection prevention means long asset lives and recurring usage, which can support relatively steady cash generation if customers keep running their facilities at current intensity.
  • What if you looked at STERIS through its earnings instead? See what STERIS's 28.1x P/E says about the price.

The issue now is whether STERIS shares at around US$232 are adequately supported by the cash flows implied in the Discounted Cash Flow (DCF) intrinsic value estimate.

If you want to test the same cash flow question beyond STERIS, compare it with companies in the solid balance sheet and fundamentals stocks screener (23 results).

Where Does STERIS Sit on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash STERIS can plausibly return to shareholders. Latest twelve month free cash flow sits at about $886.9m, and the projections used in this framework assume that future cash generation grows gradually from that base rather than swinging sharply higher or lower.

Those inputs create a picture of a mature business with relatively steady cash flows rather than a high risk turnaround story. When that stream of projected cash is discounted back and compared with the current share price of $232.14, the DCF output suggests that STERIS is broadly in line with where the market is trading today. This leaves the question of whether the implied stability matches your own view of the company’s future cash resilience. Find out what STERIS could be worth using our Discounted Cash Flow (DCF) estimate.

The STERIS Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the STERIS valuation puzzle leaves off by spelling out what would need to happen to revenue growth, margins and earnings power for the stock to trade meaningfully above or below today’s level. They sit on the platform’s Community page. Rather than relying on a single multiple or model, each narrative lays out the assumptions behind its fair value view so you can compare them with the actual numbers as they arrive over time.

One of the top community narratives on STERIS: 12% undervalued

"Continued mix shift toward recurring chemistries and services, which now account for roughly 80% of STERIS revenue versus about 20% a decade ago…"

Discover why this Narrative puts STERIS at 12% undervalued.

For STERIS, the share price is only one piece of the decision

Before you rely on any cash flow view, it is worth knowing who is actually steering STERIS and how their rewards line up with the outcomes you care about. See who runs STERIS and how they are paid.